全文获取类型
收费全文 | 6682篇 |
免费 | 616篇 |
国内免费 | 72篇 |
专业分类
耳鼻咽喉 | 56篇 |
儿科学 | 171篇 |
妇产科学 | 121篇 |
基础医学 | 842篇 |
口腔科学 | 556篇 |
临床医学 | 726篇 |
内科学 | 1359篇 |
皮肤病学 | 57篇 |
神经病学 | 557篇 |
特种医学 | 285篇 |
外科学 | 1025篇 |
综合类 | 117篇 |
一般理论 | 15篇 |
预防医学 | 601篇 |
眼科学 | 66篇 |
药学 | 458篇 |
中国医学 | 8篇 |
肿瘤学 | 350篇 |
出版年
2021年 | 90篇 |
2020年 | 62篇 |
2019年 | 101篇 |
2018年 | 107篇 |
2017年 | 89篇 |
2016年 | 103篇 |
2015年 | 102篇 |
2014年 | 169篇 |
2013年 | 242篇 |
2012年 | 291篇 |
2011年 | 382篇 |
2010年 | 206篇 |
2009年 | 178篇 |
2008年 | 324篇 |
2007年 | 412篇 |
2006年 | 370篇 |
2005年 | 334篇 |
2004年 | 299篇 |
2003年 | 310篇 |
2002年 | 296篇 |
2001年 | 129篇 |
2000年 | 150篇 |
1999年 | 115篇 |
1998年 | 111篇 |
1997年 | 100篇 |
1996年 | 95篇 |
1995年 | 86篇 |
1994年 | 61篇 |
1993年 | 55篇 |
1992年 | 104篇 |
1991年 | 76篇 |
1990年 | 101篇 |
1989年 | 75篇 |
1988年 | 92篇 |
1987年 | 90篇 |
1986年 | 90篇 |
1985年 | 68篇 |
1984年 | 70篇 |
1983年 | 73篇 |
1982年 | 54篇 |
1981年 | 47篇 |
1980年 | 44篇 |
1979年 | 45篇 |
1978年 | 59篇 |
1977年 | 62篇 |
1975年 | 48篇 |
1974年 | 48篇 |
1973年 | 41篇 |
1972年 | 51篇 |
1971年 | 41篇 |
排序方式: 共有7370条查询结果,搜索用时 0 毫秒
151.
James L. Januzzi Annabel A. Chen-Tournoux Robert H. Christenson Gheorghe Doros Judd E. Hollander Phillip D. Levy John T. Nagurney Richard M. Nowak Peter S. Pang Darshita Patel W. Franklin Peacock E. Joy Rivers Elizabeth L. Walters Hanna K. Gaggin 《Journal of the American College of Cardiology》2018,71(11):1191-1200
Background
Contemporary reconsideration of diagnostic N-terminal pro–B-type natriuretic peptide (NT-proBNP) cutoffs for diagnosis of heart failure (HF) is needed.Objectives
This study sought to evaluate the diagnostic performance of NT-proBNP for acute HF in patients with dyspnea in the emergency department (ED) setting.Methods
Dyspneic patients presenting to 19 EDs in North America were enrolled and had blood drawn for subsequent NT-proBNP measurement. Primary endpoints were positive predictive values of age-stratified cutoffs (450, 900, and 1,800 pg/ml) for diagnosis of acute HF and negative predictive value of the rule-out cutoff to exclude acute HF. Secondary endpoints included sensitivity, specificity, and positive (+) and negative (?) likelihood ratios (LRs) for acute HF.Results
Of 1,461 subjects, 277 (19%) were adjudicated as having acute HF. The area under the receiver-operating characteristic curve for diagnosis of acute HF was 0.91 (95% confidence interval [CI]: 0.90 to 0.93; p < 0.001). Sensitivity for age stratified cutoffs of 450, 900, and 1,800 pg/ml was 85.7%, 79.3%, and 75.9%, respectively; specificity was 93.9%, 84.0%, and 75.0%, respectively. Positive predictive values were 53.6%, 58.4%, and 62.0%, respectively. Overall LR+ across age-dependent cutoffs was 5.99 (95% CI: 5.05 to 6.93); individual LR+ for age-dependent cutoffs was 14.08, 4.95, and 3.03, respectively. The sensitivity and negative predictive value for the rule-out cutoff of 300 pg/ml were 93.9% and 98.0%, respectively; LR? was 0.09 (95% CI: 0.05 to 0.13).Conclusions
In acutely dyspneic patients seen in the ED setting, age-stratified NT-proBNP cutpoints may aid in the diagnosis of acute HF. An NT-proBNP <300 pg/ml strongly excludes the presence of acute HF. 相似文献152.
153.
International multicentre psychometric evaluation of patient‐reported outcome data for the treatment of Peyronie's disease 下载免费PDF全文
154.
155.
156.
Heike Hoyer-Kuhn Sina Kohbrok Ruth Volland Jeremy Franklin Barbara Hero Bodo B. Beck Bernd Hoppe 《Clinical journal of the American Society of Nephrology》2014,9(3):468-477
Background and objectives
Primary hyperoxaluria type I (PH I) is caused by deficiency of the liver-specific enzyme alanine-glyoxylate:aminotransferase (AGT). Many mutations are known to perturb AGT protein folding. Vitamin B6 (B6) is the only specific drug available for treatment. Although B6 has been used for >40 years, controlled data on B6 efficacy are lacking. Therefore, this study investigated the absolute and relative change of urinary oxalate (Uox) excretion under increasing dosages of B6, the first prospective trial to do so.Design, setting, participants, & measurements
B6 response was studied in 12 patients (7 male patients) with genetically confirmed PH I (3 Gly170Arg homozygous, 5 compound Gly170Arg and/or Phe152Ile heterozygous, and 4 negative for Gly170Arg and/or Phe152Ile mutations) and noncompromised renal function. Efficacy was defined as a 30% relative reduction in Uox excretion. B6 was administered orally starting at 5 mg/kg body weight per day and given in increments of 5 mg/kg every 6 weeks, up to a final dosage of 20 mg/kg per day at week 24. Uox and serum B6 levels were measured every 6 weeks.Results
Mean relative Uox reduction was 25.5%. Uox declined from 2.09±0.55 (mean±SD) at baseline to 1.52±0.60 mmol/1.73 m2 per day (P=0.01) at week 24. Serum B6 levels increased from 22.5±8.7 to 1217±776 ng/ml (P<0.001). Six patients showed a ≥30% relative reduction of Uox at week 24.Conclusion
This first prospective trial confirmed B6 efficacy in 50% of patients (three of three homozygous, one of five heterozygous, and two of four patients negative for the Gly170Arg and/or Phe152Ile mutations). Interestingly, no complete biochemical remission was observed, even in the homozygous Gly170Arg study participants. Future trials are necessary to learn more about genotype-related B6 response and B6 metabolism. 相似文献157.
158.
159.
Shruti Mittal Myura Nagendran Rachel H. Franklin Edward J. Sharples Peter J. Friend Stephen C. L. Gough 《Diabetologia》2014,57(10):2076-2080
Aims/hypothesis
The management of pancreatic transplantation is limited by a lack of clinically relevant early markers of graft dysfunction to enable intervention prior to irreversible damage. The aim of this study was to assess the OGTT as an early predictor of pancreatic graft failure.Methods
Patients with graft failure (return to insulin dependence) were identified from a prospectively maintained clinical database. Data from OGTTs performed within 2 weeks of the transplant were retrospectively collected for 210 subjects, 42 with graft failure (21 after simultaneous pancreas–kidney transplant and 21 after isolated pancreas transplant) matched to 168 with functioning grafts. The groups were compared to assess the relationship between early OGTT result and pancreas graft failure.Results
Mean 2 h glucose from the OGTT was significantly higher in the overall graft failure group compared with the control group (8.36 vs 6.81 mmol/l, p?=?0.014). When interpreted in combination with fasting glucose, abnormal glucose tolerance was more common in the failed graft group (50% vs 22%, p?=?0.001). In an adjusted model, abnormal glucose tolerance emerged as the most predictive independent factor for graft failure, HR 1.66 (95% CI 1.22, 2.24), p?=?0.001. These findings were consistent between the different transplant procedures performed.Conclusions/interpretation
We conclude that early post-transplant abnormal glucose tolerance is associated with later whole organ pancreas graft failure. An OGTT performed within the first month postoperatively provides an easily measurable assessment of an independent early risk factor of pancreatic graft dysfunction. 相似文献160.